@article{JTD16383,
author = {Jumpei Kashima and Yusuke Okuma and Hiroto Murata and Kageaki Watanabe and Yukio Hosomi and Tsunekazu Hishima},
title = {Chemoradiotherapy for unresectable cases of thymic epithelial tumors: a retrospective study},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {10},
year = {2017},
keywords = {},
abstract = {Background: Because of the rarity of thymic epithelial tumors (TETs), there is no treatment for managing unresectable tumors that is supported by a high level of evidence. We present here the clinical outcomes of concurrent or sequential chemoradiotherapy for patients with unresectable TETs.
Methods: We collated records for 215 patients with TETs who were treated at our institution and focused on the 20 patients who underwent chemoradiotherapy without curative-intent surgical resection.
Results: Six patients with thymoma (4%) and 14 patients with thymic carcinoma (19%) were treated with chemoradiotherapy. Six received concurrent therapy, and platinum-containing regimens were administered to 16 patients. The survival of patients with thymic carcinoma was poorer than that of patients with thymoma [median overall survival (OS), 64.1 and 31.4 months, respectively; P=0.059]. No significant difference in survival was observed between patients treated concurrently and sequentially (48.5 vs. 38.2 months, respectively, P=0.83) or between patients treated with platinum-containing regimens and other regimens (43.5 and 53.8 months, respectively, P=0.25).
Conclusions: Chemoradiotherapy for unresectable TETs can be beneficial, especially when administrated concurrently. Patients for concurrent chemoradiotherapy should be chosen carefully because of its effectiveness and toxicity.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/16383}
}